Mother to child human immunodeficiency virus (HIV) transmission: what HIV-infected women think. Our experience in Rome, Italy

2002 ◽  
Vol 13 (8) ◽  
pp. 551-553
Author(s):  
E Visconti ◽  
Lucia Pastore Celentano ◽  
Salvatore Marinaci ◽  
Giancarlo Scoppettuolo ◽  
Enrica Tamburrini
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Hiv Transmission ◽  
Childbearing Age ◽  
Highly Active ◽  
Perinatal Hiv ◽  
Significant Difference ◽  
Immunodeficiency Virus ◽  
Risk Rate ◽  
Mother To Child

Objectives: To investigate the knowledge of the risk of HIV vertical transmission as well as the feeling about the new therapy in reducing that rate. Methods: We included 152 HIV-infected women. A self reported questionnaire was administered from September to December 2000. Results: About the risk rate of transmitting HIV to their baby, 21 (13.8%) women indicated 100%; 67 (44.1%) 50-80%; 35 (23%) 10-50% and only 22 women (14.5%) answered the correct value of less than 5%. Regarding the effect of highly active antiretroviral therapy, 82 women (53.9%) considered therapy effective in reducing vertical HIV transmission, while 63 women (41.4%) considered therapy powerless in preventing mother to child HIV transmission. Any statistically significant difference in sociodemographic, clinical, viroimmunological characteristics and antiretroviral therapy emerged between the groups. Conclusions: Our data highlight the importance of providing appropriate counselling about perinatal HIV transmission to all childbearing age HIV infected women.

scholarly journals Prevention of mother-to-child HIV transmission: from the first stages to the possibility of elimination

2021 ◽  
Vol 69 (6) ◽  
pp. 107-116
Author(s):  
Olga L. Mozalyova ◽  
Anna V. Samarina
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Hiv Transmission ◽  
Transmission Rate ◽  
Preventive Treatment ◽  
Transmission Risk ◽  
Mother To Child Transmission ◽  
Child Transmission ◽  
Perinatal Hiv ◽  
Mother To Child

Despite the success in reducing mother-to-child HIV transmission rate worldwide, the problem of perinatal HIV transmission is still relevant. Sexual activity nowadays is the predominant way of transmission, therefore the number of HIV cases among women growths. This leads to an increased number of pregnancies and childbirth in HIV-infected women. Better preventive treatment has decreased the transmission risk to 1% or less. Despite this, the Russian Federation is still not among the countries where the elimination of mother-to-child transmission has been recorded. This review article focuses on the main stages of mother-to-child transmission prevention from the time that no antiretroviral therapy was available to the current stage, when highly active antiretroviral therapy is used during pregnancy, childbirth and for the treatment of newborns. The research provides a comparative analysis of modern national and international clinical recommendations for the prevention of mother-to-child HIV transmission.

scholarly journals Phosphazide (nikavir) is a highly effective drug for the treatment of HIV/AIDS infection

2017 ◽  
Vol 62 (1) ◽  
pp. 5-11 ◽  
Author(s):  
G. A. Galegov
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Hiv Transmission ◽  
Convincing Evidence ◽  
First Line ◽  
Hiv Therapy ◽  
Highly Active ◽  
Mother To Child ◽  
Prevention Of Hiv ◽  
Hiv Aids

Federation Convincing evidence for high therapeutic activity and tolerability of Phosphazide in the treatment of HIV/AIDS-infection is given. Phosphazide is currently used in various regimens of highly active antiretroviral therapy, as well as in the HIV therapy in patients with simultaneously acquired chronic hepatitis C or tuberculosis. Therapeutic possibilities of Phosphazide were clearly manifested in the prevention of HIV transmission from mother to child. There is every reason to use Phosphazide in first-line antiretroviral therapy.

Sign in / Sign up

Export Citation Format

Share Document